CSI Market
Sign In | Register

Processa Pharmaceuticals Inc (PCSA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PCSA Annual Cash Flow →
From Processa Pharmaceuticals Inc through Jun 30 2025, changes in Jun 30 2026's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-6.64
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.19
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Allowance For Loan And Lease Losses Recoveries Of Bad Debts-
Impairment Of Software Costs-
Capitalized Computer Software Impairments-
Amortization Of Rightofuse Assets-
Payments Made Directly By Investor In Partial Satisfaction Of Their Stock Subscription Receivable-
Payments Made Directly To Our Contract Research Organization For Clinical Trial Expenses By Investor In Partial Satisfaction Of Their Stock Subscription Receivable-
Operating Lease Expense-
Non Cash Acquisition Of Inprocess Research And Development-
Operating And Finance Lease Expense0.07
Increase Decrease In Due From To Related Parties-0.07
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.00
Increase (Decrease) in Accounts Payable0.60
Increase (Decrease) in Accrued Liabilities-0.45
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.27
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.45
Discontinued operations0.00
Net Cash flow from Operating Activities-5.59
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Received In Reverse Acquisition Transaction-
Acquisition Costs Related To Intangible Asset-
Payments to Acquire Restricted Certificates of Deposit0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.31
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.31
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.56
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits0.00
Other financing activities net0.00
Other net0.00
Proceeds From Advance Payment-
Proceeds From Issuance Subscription Receivable-
Transaction Costs Related To Anticipated Offering-
Transaction Costs Related To Subsequent Common Stock Offering-
Borrowings On Line Of Credit Payable From Related Party-
Shares Withheld To Pay Income Tax On Stockbased Compensation-
Line Of Credit Payable From Related Party-
Payments For Settlement Of Stock Awards-
Finance Lease Principal Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.56
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.59
Total Cash Flow-5.34
4 historic quarters locked

Sign in to unlock the full Processa Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Processa Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 14, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-038334

Figures are derived from filed reports and may be restated. Historical data is subject to revision.